Valeant jumps back into M&A, acquiring Salix after wholesale inventory issues discouraged other potential buyers. Merck more or less options a pipeline with its five-year R&D collaboration with NGM Pharma.
“The Pink Sheet” regularly provides coverage of noteworthy biopharmaceutical business deals. Here is a roundup of the most significant deals that occurred between Feb. 20-26.
Bristol-Myers Squibb Co. announced a pair of cancer immunotherapy deals on Feb. 23, inking an R&D collaboration with Rigel Pharmaceuticals Inc. and negotiating a buyout of privately held...
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.
Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.
The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.
